- Home
- KOD vs TIL Comparison
KOD vs TIL Comparison
Compare KOD & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- TIL
- Stock Information
- Founded
- KOD 2009
- TIL 2018
- Country
- KOD United States
- TIL United States
- Employees
- KOD N/A
- TIL N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- TIL Health Care
- Exchange
- KOD Nasdaq
- TIL Nasdaq
- Market Cap
- KOD 198.4M
- TIL 177.1M
- IPO Year
- KOD 2018
- TIL 2021
- Fundamental
- Price
- KOD $10.52
- TIL $31.50
- Analyst Decision
- KOD Hold
- TIL Buy
- Analyst Count
- KOD 4
- TIL 6
- Target Price
- KOD $11.75
- TIL $120.50
- AVG Volume (30 Days)
- KOD 673.8K
- TIL 109.0K
- Earning Date
- KOD 08-13-2025
- TIL 08-13-2025
- Dividend Yield
- KOD N/A
- TIL N/A
- EPS Growth
- KOD N/A
- TIL N/A
- EPS
- KOD N/A
- TIL N/A
- Revenue
- KOD N/A
- TIL N/A
- Revenue This Year
- KOD N/A
- TIL N/A
- Revenue Next Year
- KOD N/A
- TIL N/A
- P/E Ratio
- KOD N/A
- TIL N/A
- Revenue Growth
- KOD N/A
- TIL N/A
- 52 Week Low
- KOD $1.92
- TIL $10.80
- 52 Week High
- KOD $11.60
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- KOD 64.28
- TIL 61.57
- Support Level
- KOD $8.29
- TIL $26.69
- Resistance Level
- KOD $9.23
- TIL $28.85
- Average True Range (ATR)
- KOD 0.98
- TIL 2.16
- MACD
- KOD -0.16
- TIL 0.43
- Stochastic Oscillator
- KOD 74.33
- TIL 76.70
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.